Salicylic acid revisited

International Journal of Dermatology

Volumn 37, Issue 5, 1998, Pages 335-342

  Lin, Andrew N ^a   Nakatsui, Thomas ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SALICYLIC ACID;

DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG USE; HUMAN; REVIEW; SKIN DISEASE;

ADMINISTRATION, CUTANEOUS; HUMANS; KERATOLYTIC AGENTS; SALICYLIC ACID; SALICYLIC ACIDS;

EID: 0031777420     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1998.00452.x     Document Type: Review

References (51)

1. Insel PA. Analgesics-antipyretics and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbard LE, Molinoff PB, et al., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996: 617-657.
2. Littleton Jr F. Warfarin and topical salicylates. J Am Med Assoc 1990; 263: 2888.
3. Loden M, Bostrom P, Kneczke M. Distribution and keratolytic effect of salicylic acid and urea in human skin. Skin Pharmacol 1995; 8: 173-178.
4. Roberts DL, Marshall R, Marks R. Detection of the action of salicylic acid on the normal human stratum corneum. Br J Dermatol 1980; 103: 191-196.
5. Davies M, Marks R. Studies on the effect of salicylic acid on normal skin. Br J Dermatol 1976; 95: 187-192.
6. Huber C, Christophers E. "Keratolytic" effect of salicylic acid. Arch Dermatol Res 1977; 257: 293-297.
7. Marks R. Topical therapy for psoriasis: general principles. Dermatologic Clinics 1984; 2: 383-388.
8. United States Pharmacopeial Convention I. Salicylic acid: topical. In: Drug Information for the Health Care Professional. Rockville: United States Pharmacopeial Convention, Inc., 1996: 2607-2611.
9. Larko O. Problem sites: scalp, palm and sole, and nail. Dermatologic Clinics 1995; 13: 771-777.
10. Baden HP, Alper JC. A keratolytic gel containing salicylic acid in propylene glycol. J Invest Dermatol 1973; 61: 330-333.
11. Buselmeier TJ. Combination urea and salicylic acid ointment nail avulsion in nondystrophic nails: a follow-up observation. Cutis 1980; 25: 397-405.
12. Leyden JL, Shalita AR. Rational therapy for acne vulgaris: an update on topical treatment. J Am Acad Dermatol 1986; 15: 907-914.
13. Christophers E, Sterry W. Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., eds. Dermatology in General Medicine. New York: McGraw-Hill, 1993: 489-514.
14. Polano MK. Skin Therapeutics: Prescription and Preparation (Materia Medica Dermatologica). Amsterdam: Elsevier, 1952; 57-58, 111.
15. Shaath NA. Evolution of modern sunscreen chemicals. In: Lowe NJ, Shaath NA, eds. Sunscreens: Development, Evaluation and Regulatory Aspects. New York: Marcel Dekker, Inc., 1990: 3-35.
16. Lebwohl M, Martinez J, Weber P, et al. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy. J Am Acad Dermatol 1995; 32: 469-471.
17. Harvey SC. Topical drugs. In: Osol A, ed. Remington's Pharmaceutical Sciences. Easton, PA: Mack Publishing Co, 1975: 724-725.
18. Wester RC, Noonan PK, Maibach HI. Effect of salicylic acid on the percutaneous absorption of hydrocortisone: in vivo studies in the Rhesus monkey. Arch Dermatol 1978; 114: 1162-1164.
19. Tauber U, Weiss C, Matthes H. Does salicylic acid increase the percutaneous absorption of diflucortolone-21-valerate? Skin Pharmacol 1993; 6: 276-281.
20. Kvorning SA. On ointments containing salicylic acid. Acta Dermatol Venereol (Stockh) 1954; 34: 89-91.
21. Stolar ME, Rossi GV, Barr M. The effect of various ointment bases on the percutaneous absorption of salicylates. I. Effect of type of ointment base. J Am Pharm Assoc 1960; 49: 144-147.
22. Birmingham BK, Greene DS, Rhodes CT. Systemic absorption of topical salicylic acid. Int J Dermatol 1979; 18: 228-231.
23. Taylor JR, Halprin KM. Percutaneous absorption of salicylic acid. Arch Dermatol 1975; 111: 740-743.
24. Dwyer CM, McCloskey RH, Kerr REI. Poisoning from topical salicylic acid. Postgrad Med J 1994; 70: 146.
25. Abdel-Magid EHM, Ahmned F-REAA. Salicylate intoxication in an infant with ichthyosis transmitted through skin ointment - a case report. Pediatrics 1994; 94: 939-940.
26. Maurer TA, Winter ME, Koo J, et al. Refractory hypoglycemia: a complication of topical salicylate therapy. Arch Dermatol 1994; 130: 1455-1456.
27. Weiss JF, Lever WF. Percutaneous salicylic acid intoxication in psoriasis. Arch Dermatol 1964; 90: 614-619.
28. Lindsey CP. Two cases of fatal salicylate poisoning after topical application of an antifungal solution. Med J Australia 1968; 1: 353-354.
29. Galea P, Goel KM. Salicylate poisoning in dermatological treatment. Arch Dis Childhood 1990; 65: 335.
30. Shupp DL. An unusual case of salicylate toxicity. J Am Acad Dermatol 1986; 15: 300-301.
31. Perlman LV. Salicylate intoxication from skin application. N Engl J Med 1966; 274: 164.
32. Cawley EP, Peterson NT, Wheeler CE. Salicylic acid poisoning in dermatological therapy. J Am Med Assoc 1953; 151: 372-374.
33. Davies MG, Briffa DV, Greaves MW. Systemic toxicity from topically applied salicylic acid. Br Med J 1979; 1: 661.
34. Pec J, Strmenova M, Palencarova E, et al. Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis 1992; 50: 307-309.
35. Soyka PA, Soyka LF. Absorption of salicylic acid. J Am Med Assoc 1980; 244: 660-661.
36. Young CJ. Salicylate intoxication from cutaneous absorption of salicylic acid. South Med J 1952; 45: 1075-1077.
37. Ward RS, Jones RD. Successful treatment of a harlequin fetus. Arch Dis Childhood 1989; 64: 1309-1310.
38. Leslie-Roberts H. On the absorption of salicylic acid by the human skin. Br J Dermatol Syphilis 1928; 40: 325-344.
39. Anderson JAR, Ead RD. Percutaneous salicylate poisoning. Clin Exper Dermatol 1979; 4: 349-351.
40. Gorter E. On salicylate poisoning in children. Acta Paediatr 1949; 38: 170-177.
41. Summons WH. Poisoning from skin absorption of salicylic acid. Intercolonial Med J Australasia 1904; 9: 518-519.
42. Raschke R, Arnold-Capell PA, Richeson R, et al. Refractory hypoglycemia secondary to topical salicylate intoxication. Arch Intern Med 1991; 151: 591-593.
43. Smith WO, Lyons DL. Metabolic acidosis associated with percutaneous absorption of salicylic acid. Oklahoma State Med Assoc J 1980; 73: 7-8.
44. Heng MCY. Local necrosis and interstitial nephritis due to topical methyl salicylate and menthol. Cutis 1987; 39: 442-444.
45. Bartle B, Morra P, Walker S, et al. Salicylate toxicity -from topical methylsalicylate. On Continuing Practice 1991; 19: 23-25.
46. Paynter AS, Alexander FW. Salicylate intoxication caused by teething ointment. The Lancet 1979; 2: 1132.
47. Goh CL, Ng SK. Contact allergy to salicylic acid. Contact Dermatitis 1986; 14: 114.
48. Morgan JK. Iatrogenic epidermal sensitivity. Br J Clin Prac 1968; 22: 261-264.
49. Rudzki E, Koslowska A. Sensitivity to salicylic acid. Contact Dermatitis 1976; 2: 178.
50. Hindson C. Contact eczema from methyl salicylate reproduced by oral aspirin. Contact Dermatitis 1977; 3: 348-349.
51. Lachapelle J-M, Leroy B. Allergic contact dermatitis to colophony included in the formulation of flexible collodion BP, the vehicle of a salicylic and lactic acid wart paint. Dermatologic Clinics 1990; 8: 143-146.